OTR Therapeutics Secures $100 Million Series A to Build Capital-Efficient R&D Platform in Shanghai
Key Insights
OTR Therapeutics (search), a Shanghai-based biotech, raised $100 million in Series A funding led by True Light Capital (search), LAV (search), Pfizer Ventures (search), and Sirona Capital (search) to advance early-stage innovations into global therapies.
The company operates a capital-efficient R&D hub model that combines internal drug discovery with external asset acquisition across oncology (search), immunology, cardiometabolic diseases (search), and neurology (search).
OTR recently acquired a preclinical neurological program with "best-in-class potential" and plans to advance multiple assets simultaneously through its integrated platform.
OTR Therapeutics (search), a Shanghai-based biotechnology company, has emerged from stealth mode with a $100 million Series A financing round that closed in June 2025. The funding, led by True Light Capital (search), LAV (search), Pfizer Ventures (search), and Sirona Capital (search), represents one of the most significant early-stage biotech financings in China this year and underscores growing investor confidence in capital-efficient R&D models.
Strategic R&D Hub Model
Founded in March 2025, OTR Therapeutics (search) has developed a distinctive approach to drug development that combines internal discovery capabilities with strategic external asset acquisition. The company focuses on transforming early-stage innovations into globally impactful therapies across oncology (search), immunology and inflammation (search), cardiometabolic diseases (search), and neurology (search).
"We believe the biopharma industry is shifting towards more capital-efficient and specialized R&D models," said Yi Shi, Managing Director at LAV (search). "OTR Therapeutics (search) is at the forefront of this evolution, demonstrating how a focused, integrated framework can expedite the journey of translating early-stage innovation into global clinical development."
The company's model involves discovering internally or acquiring externally high-potential assets at preclinical or early clinical stages, then advancing them through a centralized R&D hub designed for speed, quality, and efficiency. This approach allows OTR to progress multiple candidates toward global clinical development simultaneously.
Zhangjiang Biotech Cluster Advantage
The Series A proceeds will primarily fund expansion of OTR's R&D hub in Shanghai's Zhangjiang Hi-Tech Park, often described as China's "biopharma valley." The location houses hundreds of R&D centers and multinational pharmaceutical operations, providing OTR with access to a robust biotech ecosystem.
OTR operates from Bayer Co.Lab Shanghai (search), a life science incubator that provides advanced laboratory facilities, global pharmaceutical networks, and potential co-development pathways. This infrastructure support gives the young company significant advantages as it pursues global clinical ambitions from its inception.
The company's integrated R&D engine combines in-house scientific teams with a network of global collaborators across the United States, Europe, and Asia, positioning it to meet international regulatory standards from day one.
Expanding into Neurology
Alongside the funding announcement, OTR disclosed its acquisition of a preclinical neurological program described as having "best-in-class potential" for diseases with high unmet medical need. While specific details remain undisclosed, this acquisition signals the company's expansion beyond its initial focus areas into neurology (search), a field where large pharmaceutical companies are actively seeking innovation.
The neurological program will be advanced in parallel with OTR's internal discovery projects, demonstrating the company's portfolio approach to drug development. This strategy provides investors with multiple opportunities for success rather than dependence on a single flagship candidate.
Leadership and Investor Confidence
OTR's founding team includes CEO Zhui Chen, Ph.D., who previously co-founded Abbisko Therapeutics (search) and sold tumor drug pimicotinib to Merck KGaA, along with Shannon Chuai, Ph.D., and Yuan Shi, Ph.D. The team brings combined scientific, clinical, and operational experience that investors cite as critical to the company's potential success.
"Pfizer Ventures (search) identifies and invests in emerging companies who are developing innovative medicines and technologies that have the potential to shape the future of our industry," said Michael Baran, Partner at Pfizer Ventures. "To this end, we're pleased to be able to support OTR Therapeutics (search) as it scales its R&D capabilities and builds a portfolio of potentially transformative therapies."
True Light Capital (search), a wholly-owned subsidiary of Temasek (search) with approximately $4 billion in assets under management, brings deep knowledge of China-linked growth stories and expertise in innovation-driven businesses in Greater China.
Market Context and Industry Evolution
The funding round occurs as the global pharmaceutical industry faces rising R&D costs and longer development timelines, forcing companies to adopt more selective and capital-efficient approaches. Large pharmaceutical companies increasingly seek de-risked assets from nimble, specialized biotechnology companies, creating opportunities for platforms like OTR's.
Chen frames OTR as a "next-generation biotech" that responds to these new realities by combining rigorous science, lean operations, and a portfolio approach to early-stage assets. The company's model aligns with investor preferences for platform-like companies that can generate multiple assets while maintaining global market focus and cost efficiency.
The Series A round demonstrates that global pharmaceutical venture capital firms remain willing to commit significant capital to China-based biotechnology companies, provided the business model is focused, scalable, and designed for international markets. OTR's success in attracting both global pharmaceutical investors and regional heavyweights reflects the company's positioning as a bridge between early scientific innovation and global late-stage development.